BioSpace News Archive

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that George Scangos, Ph.D., chief executive officer will virtually present at the 39th Annual J.P. Morgan Healthcare Conference

Oncternal Therapeutics (Nasdaq: ONCT), today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat hosted by H.C. Wainwright on Monday, January 11, 2021. The discussion may cover Oncternal’s recent progress, upcoming catalysts, and plans for 2021. Please see additional details below: H.C. Wainwright BioConnect 2021 Conference (Virtual) Title: On

89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, provided a corporate update, including its roadmap for advancing BIO89-100 in 2021.

BioLife Solutions , Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced the promotion of Sarah Aebersold to the position of Global Vice President, Human Resources.

CCT Puts Its 50-Plus Years’ Experience Safeguarding Biomedical Products in Transit to Work to Aid Massive COVID-19 Vaccine Distribution Effort

Emboline, Inc., a privately held medical technology company focused on reducing stroke during transcatheter heart procedures, today announced it completed raising over $10 million in Series C funding, from new and existing investors.

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the virtual J.P. Morgan Healthcare Conference on Monday January 11, 2021 at 11:50 a.m. P

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to initiate a Phase I clinical trial of Precigen’s PRGN-2012,

Marius Pharmaceuticals, a specialty pharmaceutical company focusing on treating conditions that are primarily associated with testosterone deficiency, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of KYZATREX®

Presentation and webcast to take place at 10 a.m. ET on January 14